• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.25% Nasdaq Up0.65%

    Regulus Therapeutics Inc. (RGLS)

    -NasdaqGM
    5.80 Up 0.03(0.52%) May 27, 4:00PM EDT
    Income StatementGet Income Statement for:
    View: Annual Data | Quarterly DataAll numbers in thousands
    Period EndingMar 31, 2016Dec 31, 2015Sep 30, 2015Jun 30, 2015
    Total Revenue 489   10,860   1,865   3,834  
    Cost of Revenue -   -   -   -  
    Gross Profit 489   10,860   1,865   3,834  
    Operating Expenses
    Research Development16,764  12,794  10,965  19,201  
    Selling General and Administrative5,103  5,427  4,245  5,814  
    Non Recurring -   -   -   -  
    Others -   -   -   -  
    Total Operating Expenses -   -   -   -  
    Operating Income or Loss (21,378) (7,361) (13,345) (21,181)
    Income from Continuing Operations
    Total Other Income/Expenses Net190  169  335  152  
    Earnings Before Interest And Taxes(21,188)(7,192)(13,010)(21,029)
    Interest Expense24  30  6  8  
    Income Before Tax(21,212)(7,222)(13,016)(21,037)
    Income Tax Expense(5)4  (16)(2)
    Minority Interest -   -   -   -  
    Net Income From Continuing Ops(21,207)(7,226)(13,000)(21,035)
    Non-recurring Events
    Discontinued Operations -   -   -   -  
    Extraordinary Items -   -   -   -  
    Effect Of Accounting Changes -   -   -   -  
    Other Items -   -   -   -  
    Net Income (21,207) (7,226) (13,000) (21,035)
    Preferred Stock And Other Adjustments -   -   -   -  
    Net Income Applicable To Common Shares (21,207) (7,226) (13,000) (21,035)

    Sign Up for a Free Trial to EDGAR Online Premium!
    Get the critical business and financial information you need for more than 15,000 U.S. public companies.
    Sign Up Now - Learn More

    Currency in USD.